Safety and Immunogenicity Study of Live Attenuated Vaccine Against Varicella Without Gelatin

Observational Objectives:

To describe the safety of evaluated vaccine, in children aged ≥ 1th birthday and ≤ 12th birthday.

To describe the immunogenicity of evaluated vaccine, in children aged ≥ 1th birthday and ≤ 12th birthday.

Inclusion criteria

• Parent/legal acceptable representative is willing and able to understand the protocol requirements and provide informed consent
• Participant is considered to be in good health including the body and mental status on the basis of reported medical history and limited physical examination and live in local ≥ 12 months
• Participant is aged ≥ 1 year to ≤ 12 years
• Body temperature ≤ 37.0℃
• Participant without preventive inoculation of varicella vaccine and previous history of chickenpox and zoster

Exclusion criteria

• Known allergy to any constituent of the vaccine
• Reported the history of allergies, convulsions, epilepsy, mental illness and brain disease and clear serious systemic reaction
• Known bleeding disorder
• Known or suspected impairment of immunologic function, or receipt of immunosuppressive therapy or immunoglobulin since birth
• Participation in any other interventional clinical trial
• An acute illness with or without fever (temperature > 37.0℃) in the latest week preceding enrollment in the trial
• Inoculated other vaccines, immunoglobulin or investigational drugs within 4 weeks prior to participation in the study
• Reported clearly the infection of the upper respiratory tract with 6 months
• Clinical Manifestation of Metabolic, blood system, lungs, heart, the gastrointestinal tract, nervous system, kidneys, urinary system, endocrine, liver disease or malignant tumor
• Any condition which, in the opinion of the investigator, would pose a health risk to the subject or interfere with the vaccine